Meeting
2023 ASCO Genitourinary Cancers Symposium
Real-world (RW) prevalence of adverse events (AEs) among patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC).
Authors
Umang Swami
Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT
Umang Swami , Bin Xie , Krishnan Ramaswamy , Nader N. El-Chaar , Wei Gao , Hongbo Yang , Yao Wang , Christopher Young , Lisa Mucha
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 109)
DOI
10.1200/JCO.2023.41.6_suppl.109
Abstract #
109
Poster Bd #
D5
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A randomized, open label, multicenter, phase 3, 2-arm study of androgen deprivation with leuprolide (L), ± docetaxel (D) for clinically asymptomatic prostate cancer (PC) subjects with a rising PSA following definitive local therapy: Safety results.
First Author: Michael J. Morris
Poster
2024 ASCO Genitourinary Cancers Symposium
Apalutamide (APA) plus intermittent versus continuous androgen-deprivation therapy (ADT) in participants (pts) with metastatic castration-sensitive prostate cancer (mCSPC): LIBERTAS phase 3 study design.
First Author: Arun Azad
Poster
2024 ASCO Genitourinary Cancers Symposium
Understanding variation in treatment intensification for de novo metastatic castration-sensitive prostate cancer (mCSPC): A population-based cohort study.
First Author: Christopher J.D. Wallis
Poster
2024 ASCO Genitourinary Cancers Symposium
Survival Outcomes of APA as a Starting treatment: Impact in real-world patients with mCSPC (OASIS)
First Author: Benjamin L. Maughan